Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

PRA HEALTH SCIENCES, INC. : Submission of Matters to a Vote of Security Holders, Other Events (form 8-K)

06/16/2021 | 04:51pm EDT

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 15, 2021, PRA Health Sciences, Inc. ("PRA") held a special meeting of its stockholders (the "Special Meeting"). As of the close of business on April 26, 2021, the record date for the Special Meeting, 64,795,400 shares of common stock, $0.01 par value per share, of PRA (the "PRA Common Stock"), were outstanding and entitled to vote. A total of 52,801,348 shares of PRA Common Stock were voted in person or by proxy, representing approximately 81.48% of the shares entitled to be voted, which constituted a quorum to conduct business at the Special Meeting. The following are the final voting results on proposals considered and voted upon at the Special Meeting, all of which are described in PRA's Joint Proxy Statement/Prospectus, which was filed with the U.S. Securities and Exchange Commission on April 28, 2021.

Each of the proposals was approved by the requisite vote of PRA's stockholders.

Proposal 1 - To adopt the Agreement and Plan of Merger, dated as of February 24, 2021, by and among ICON plc ("ICON"), PRA Health Sciences, Inc. ("PRA"), ICON US Holdings Inc., a wholly owned subsidiary of ICON ("US HoldCo"), and Indigo Merger Sub, Inc., a wholly owned subsidiary of ICON and US HoldCo (such agreement, as it may be amended from time to time, the "merger agreement" and such proposal, the "PRA merger agreement proposal").

PRA's stockholders approved the PRA merger agreement proposal.

   For       Against   Abstain
52,696,425    8,219    96,704

Proposal 2 - To approve, on an advisory (non-binding) basis, the executive officer compensation that will or may be paid to PRA's named executive officers that is based on or otherwise relates to the transactions contemplated by the merger agreement (the "PRA compensation proposal").

PRA's stockholders approved the PRA compensation proposal.

   For       Against   Abstain
52,293,719   343,661   163,968

Proposal 3 - To approve the adjournment of the PRA stockholder meeting to solicit additional proxies if there are not sufficient votes at the time of the PRA stockholder meeting to approve the PRA merger agreement proposal or to ensure that any supplement or amendment to the accompanying joint proxy statement/prospectus is timely provided to PRA stockholders (the "PRA adjournment proposal").

PRA's stockholders approved the PRA adjournment proposal, if necessary, but an adjournment was not necessary in light of adoption of the merger agreement.

   For        Against    Abstain
48,962,035   3,721,701   117,612

Item 8.01        Other Events.

Based on the results of the Special Meeting, subject to the satisfaction or waiver of the remaining closing conditions under the merger agreement, the transactions contemplated by the merger agreement are expected to be consummated on July 1, 2021.

Cautionary Note Regarding Forward-Looking Statements

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally include statements regarding the potential transaction between ICON and PRA, including any statements regarding the expected timetable for completing the potential transaction, the ability to complete the potential transaction, the expected benefits of the potential transaction (including anticipated synergies, projected financial information and future opportunities) and any other statements regarding ICON's and PRA's future expectations, beliefs, plans, objectives, results of operations, financial condition and cash flows, or future events or performance. These statements are often, but not always, made through the use of words or phrases such as "anticipate," "intend," "plan," "believe," "project," "estimate," "expect," "may," "should," "will" and similar expressions. All such forward-looking statements are based on current expectations of ICON's and PRA's management and therefore involve estimates and assumptions that are subject to risks, uncertainties and other factors that could cause actual results to differ materially from the results expressed in the statements. Key factors that could cause actual results to differ materially from those projected in the forward-looking statements include uncertainties as to the timing to consummate the potential transaction; the risk that a condition to closing the potential transaction may not be satisfied; litigation relating to the potential transaction that has been or could be instituted against ICON, PRA or their respective directors; the effects of disruption to ICON's or PRA's respective businesses; restrictions during the pendency of the potential transaction that may impact ICON's or PRA's ability to pursue certain business opportunities or strategic transactions; the effect of this communication on ICON's or PRA's stock prices; transaction costs; ICON's ability to achieve the benefits from the proposed transaction; ICON's ability to effectively integrate acquired operations into its own operations; the ability of ICON or PRA to retain and hire key personnel; unknown liabilities; and the diversion of management time on transaction-related issues. Other important factors that could cause actual results to differ materially from those in the forward-looking statements include the effects of industry, market, economic, political or regulatory conditions outside of ICON's or PRA's control (including public health crises, such as pandemics and epidemics); risks regarding PRA's ability to maintain large customer contracts or enter into new contracts; PRA's ability to attract suitable investigators and patients for its clinical trials; PRA's ability to keep pace with rapid technological change; PRA's potential liability if a patient is harmed; and the factors set forth under the heading "Risk Factors" of ICON's Annual Report on Form 20-F and PRA's Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q, and in subsequent filings with the U.S. Securities and Exchange Commission (the "SEC"). These risks, as well as other risks associated with the potential transaction, are more fully discussed in the joint proxy statement/prospectus filed with the SEC in connection with the proposed transaction. Other unpredictable or unknown factors not discussed in this communication could also have material adverse effects on forward-looking statements. Neither ICON nor PRA assumes any obligation to update any forward-looking statements, except as required by law. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof.

© Edgar Online, source Glimpses

07/21ICON PUBLIC : Posts Higher Q2 Results from Year Ago, Updates Guidance -- Stock D..
07/06PRA HEALTH SCIENCES : Mizuho Securities Starts PRA Health Sciences at Neutral wi..
07/02PRA HEALTH SCIENCES, INC.(NASDAQGS : PRAH) dropped from S&P Global BMI Index
07/02PRA HEALTH SCIENCES, INC.(NASDAQGS : PRAH) dropped from S&P 1000
07/02PRA HEALTH SCIENCES, INC.(NASDAQGS : PRAH) dropped from S&P 400 Health Care
07/02PRA HEALTH SCIENCES, INC.(NASDAQGS : PRAH) dropped from S&P 400
07/02PRA HEALTH SCIENCES, INC.(NASDAQGS : PRAH) dropped from S&P Composite 1500
07/01PRA HEALTH SCIENCES : Senior Secured Credit Facilities (Form 8-K)
07/01PRA HEALTH SCIENCES : Completion of Acquisition or Disposition of Assets (Form 8..
More news
Financials (USD)
Sales 2020 3 183 M - -
Net income 2020 197 M - -
Net Debt 2020 967 M - -
P/E ratio 2020 41,3x
Yield 2020 -
Capitalization 10 705 M 10 705 M -
EV / Sales 2019 2,69x
EV / Sales 2020 2,83x
Nbr of Employees 18 100
Free-Float 100,0%
Duration : Period :
PRA Health Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Kent Thoelke Chief Scientific Officer & Executive VP
Isaac Rodriguez-Chavez Senior VP-Scientific & Clinical Affairs
Tami Klerr-Naivar Chief Business Development & Marketing Officer
Samir Shah President-Strategic Solutions & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.221.50%140 065
LONZA GROUP AG20.60%55 634
CELLTRION, INC.-26.60%31 265
SEAGEN INC.-18.34%25 955